Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)
WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in billions lost from US unverified list
GSK is tapping into WuXi Biologics’ T cell-engaging antibodies in a deal worth as much as $1.5 billion, as the UK …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
